Catalyst Wire Dossier Catalyst Wire Dossier

GLSI-100 (GP2 + GM-CSF)

GLSI-100 · Greenwich LifeSciences, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GLSI-100 (GP2 + GM-CSF), covering 2026-03-19 to 2026-03-19. Get the full timeline:

Most recent: Clinical Trial Update: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects [Phase 3]

See pricing